文献速递食管与纵隔外科

转移性食管癌中根治性放疗与手术的作用:基于NCDB的分析

The Role of Definitive Radiation and Surgery in Metastatic Esophageal Cancer: An NCDB Investigation.
PubMed 文献 · Ann Thorac Surg · 2020-10-20

研究基于美国国家癌症数据库2004–2015年28,101例转移性食管癌患者,比较接受化疗联合根治剂量放疗(部分联合食管切除术)者的生存。中位随访11.1个月,3219例接受放疗者中仅202例(6.2%)行食管切除术;全体、放疗者、放疗联合手术者的中位总生存分别为6.6、11.5、30.2个月。多因素分析示食管切除术与低肿瘤分级与更高总生存相关,肝、骨转移与更差总生存相关。

要点

  • 转移性食管癌总体预后差,全体中位总生存仅6.6个月。
  • 放疗联合食管切除术者中位总生存达30.2个月,术后中位总生存23.7个月。
  • 肝或骨转移者更少接受食管切除术且总生存更差。

核心结论

  • 对主要非内脏、非骨转移的转移性食管癌部分患者,积极局部治疗可能带来较好生存。

研究设计与样本

  • 回顾性队列研究,基于美国国家癌症数据库2004–2015年28,101例转移性食管癌患者,其中3219例接受根治剂量放疗,202例(6.2%)联合食管切除术。

主要发现

  • 中位随访11.1个月,放疗组中位年龄64岁、放疗剂量50.4 Gy,手术组中位年龄60岁。
  • 全体、放疗组、放疗联合手术组的中位总生存分别为6.6、11.5、30.2个月。
  • 手术患者术后中位总生存为23.7个月。
  • 多因素分析中食管切除术与低肿瘤分级与更高总生存相关,诊断时肝、骨转移与更差总生存相关。

临床怎么用

  • 对非内脏、非骨转移的转移性食管癌可评估积极局部治疗的获益可能。

局限性

  • 为数据库回顾性分析,原文摘要未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 40% of patients with esophageal cancer present with metastatic disease. Survival with palliative treatment is poor, and the benefit of aggressive focal therapies is unclear. This study aimed to identify a subset of patients with metastatic esophageal cancer with favorable outcomes after curative doses of radiation therapy, esophagectomy, or both. METHODS: Between 2004 and 2015, the study investigators found 28,101 patients with metastatic esophageal cancer in the National Cancer Database and identified those who underwent chemotherapy and definitive radiation therapy with or without surgery over the study period. The study compared the estimated median overall survival (OS) of all patients with metastatic esophageal cancer with the estimated median OS of patients with metastatic esophageal cancer who underwent radiation therapy with or without surgery. Multivariable analysis was used to examine clinical and pathologic factors associated with OS. RESULTS: At a median follow-up of 11.1 months, 3219 patients with a median age of 64 years and a radiation dose of 50.4 Gy were identified. Only 202 (6.2%) patients undergoing definitive-dose radiation therapy underwent esophagectomy, with a median age of 60 years. The median OS durations for all patients, for patients treated with radiation, and for patients treated with radiation therapy in combination with esophagectomy were 6.6, 11.5, and 30.2 months, respectively. Among patients undergoing surgery, median OS after surgery was 23.7 months. Patients with lung, liver, or bone metastases were less likely to undergo esophagectomy. On multivariable analysis, esophagectomy and low tumor grade were associated with higher OS, whereas liver and bone metastases at diagnosis were associated with worse OS. CONCLUSIONS: This analysis suggests that select subsets of patients with primarily nonvisceral, nonosseous metastatic esophageal cancer have favorable survival and may potentially benefit from aggressive local therapies.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Seyedin SN, Parekh KR, Ginader T, et al. The Role of Definitive Radiation and Surgery in Metastatic Esophageal Cancer: An NCDB Investigation. Ann Thorac Surg. 2020. PMID: 33096068. doi:10.1016/j.athoracsur.2020.08.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。